538 related articles for article (PubMed ID: 33243932)
1. Tumors establish resistance to immunotherapy by regulating T
Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
[TBL] [Abstract][Full Text] [Related]
2. Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors.
Robles O; Jackson JJ; Marshall L; Talay O; Chian D; Cutler G; Diokno R; Hu DX; Jacobson S; Karbarz E; Kassner PD; Ketcham JM; McKinnell J; Meleza C; Reilly MK; Riegler E; Shunatona HP; Wadsworth A; Younai A; Brockstedt DG; Wustrow DJ; Zibinsky M
J Med Chem; 2020 Aug; 63(15):8584-8607. PubMed ID: 32667798
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
[TBL] [Abstract][Full Text] [Related]
4. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.
Chang DK; Sui J; Geng S; Muvaffak A; Bai M; Fuhlbrigge RC; Lo A; Yammanuru A; Hubbard L; Sheehan J; Campbell JJ; Zhu Q; Kupper TS; Marasco WA
Mol Cancer Ther; 2012 Nov; 11(11):2451-61. PubMed ID: 22869555
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T
Jackson JJ; Ketcham JM; Younai A; Abraham B; Biannic B; Beck HP; Bui MHT; Chian D; Cutler G; Diokno R; Hu DX; Jacobson S; Karbarz E; Kassner PD; Marshall L; McKinnell J; Meleza C; Okal A; Pookot D; Reilly MK; Robles O; Shunatona HP; Talay O; Walker JR; Wadsworth A; Wustrow DJ; Zibinsky M
J Med Chem; 2019 Jul; 62(13):6190-6213. PubMed ID: 31259550
[TBL] [Abstract][Full Text] [Related]
6. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer.
Maeda S; Murakami K; Inoue A; Yonezawa T; Matsuki N
Cancer Immunol Res; 2019 Jul; 7(7):1175-1187. PubMed ID: 31160277
[TBL] [Abstract][Full Text] [Related]
7. [Anti-CCR4 mAb and regulatory T cells].
Kurose K; Ohue Y; Oka M
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
[TBL] [Abstract][Full Text] [Related]
8. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
[TBL] [Abstract][Full Text] [Related]
9. EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22.
Jorapur A; Marshall LA; Jacobson S; Xu M; Marubayashi S; Zibinsky M; Hu DX; Robles O; Jackson JJ; Baloche V; Busson P; Wustrow D; Brockstedt DG; Talay O; Kassner PD; Cutler G
PLoS Pathog; 2022 Jan; 18(1):e1010200. PubMed ID: 35025968
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T cells: a potential target in cancer immunotherapy.
Shitara K; Nishikawa H
Ann N Y Acad Sci; 2018 Apr; 1417(1):104-115. PubMed ID: 29566262
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue Y; Nishikawa H
Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
[TBL] [Abstract][Full Text] [Related]
12. CCR4 as a novel molecular target for immunotherapy of cancer.
Ishida T; Ueda R
Cancer Sci; 2006 Nov; 97(11):1139-46. PubMed ID: 16952304
[TBL] [Abstract][Full Text] [Related]
13. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
[TBL] [Abstract][Full Text] [Related]
14. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
[TBL] [Abstract][Full Text] [Related]
15. CCL17 acts as an antitumor chemokine in micromilieu-driven immune skewing.
Li Y; Cao H; Jiang Z; Yan K; Shi J; Wang S; Wang F; Wang W; Li X; Sun N; Liu L; Chen L; Chen Y; Guo R; Song Y
Int Immunopharmacol; 2023 May; 118():110078. PubMed ID: 37001380
[TBL] [Abstract][Full Text] [Related]
16. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
17. Frequency, suppressive capacity, recruitment and induction mechanisms of regulatory T cells in sinonasal squamous cell carcinoma and nasal inverted papilloma.
Lou H; Fang J; Li P; Zhou W; Wang Y; Fan E; Li Y; Wang H; Liu Z; Xiao L; Wang C; Zhang L
PLoS One; 2015; 10(5):e0126463. PubMed ID: 26020249
[TBL] [Abstract][Full Text] [Related]
18. Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy.
Viney JM; Andrew DP; Phillips RM; Meiser A; Patel P; Lennartz-Walker M; Cousins DJ; Barton NP; Hall DA; Pease JE
J Immunol; 2014 Apr; 192(7):3419-27. PubMed ID: 24563252
[TBL] [Abstract][Full Text] [Related]
19. CCR4 and its ligands: from bench to bedside.
Yoshie O; Matsushima K
Int Immunol; 2015 Jan; 27(1):11-20. PubMed ID: 25087232
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.
Gobert M; Treilleux I; Bendriss-Vermare N; Bachelot T; Goddard-Leon S; Arfi V; Biota C; Doffin AC; Durand I; Olive D; Perez S; Pasqual N; Faure C; Ray-Coquard I; Puisieux A; Caux C; Blay JY; Ménétrier-Caux C
Cancer Res; 2009 Mar; 69(5):2000-9. PubMed ID: 19244125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]